HC Wainwright Brokers Increase Earnings Estimates for RCUS

Arcus Biosciences, Inc. (NYSE:RCUS) – Investment analysts at HC Wainwright upped their Q1 2026 earnings per share (EPS) estimates for shares of Arcus Biosciences in a note issued to investors on Thursday, February 26th. HC Wainwright analyst E. Bodnar now expects that the company will earn ($1.01) per share for the quarter, up from their prior estimate of ($1.18). HC Wainwright currently has a “Buy” rating and a $32.00 target price on the stock. The consensus estimate for Arcus Biosciences’ current full-year earnings is ($3.15) per share. HC Wainwright also issued estimates for Arcus Biosciences’ Q2 2026 earnings at ($1.05) EPS, Q3 2026 earnings at ($1.09) EPS, Q4 2026 earnings at ($1.04) EPS, FY2026 earnings at ($4.66) EPS, FY2027 earnings at ($3.62) EPS, FY2028 earnings at ($2.26) EPS and FY2029 earnings at ($0.71) EPS.

RCUS has been the subject of a number of other reports. Wall Street Zen upgraded shares of Arcus Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Bank of America boosted their price objective on Arcus Biosciences from $17.00 to $26.00 and gave the stock a “neutral” rating in a research report on Friday, November 28th. The Goldman Sachs Group raised Arcus Biosciences from a “neutral” rating to a “buy” rating and raised their target price for the company from $16.00 to $28.00 in a report on Monday, January 12th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcus Biosciences in a report on Wednesday, January 21st. Finally, UBS Group reissued a “buy” rating on shares of Arcus Biosciences in a research report on Monday, December 15th. Seven analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $29.33.

Arcus Biosciences Stock Performance

NYSE:RCUS opened at $20.36 on Monday. The firm has a market capitalization of $2.55 billion, a PE ratio of -6.17 and a beta of 0.85. Arcus Biosciences has a 1 year low of $6.50 and a 1 year high of $26.40. The company has a current ratio of 4.36, a quick ratio of 4.36 and a debt-to-equity ratio of 0.16. The firm’s fifty day simple moving average is $21.57 and its 200 day simple moving average is $18.56.

Arcus Biosciences (NYSE:RCUS) last released its quarterly earnings results on Wednesday, February 25th. The company reported ($0.89) EPS for the quarter, beating analysts’ consensus estimates of ($1.11) by $0.22. Arcus Biosciences had a negative net margin of 142.91% and a negative return on equity of 65.77%. The company had revenue of $33.00 million for the quarter, compared to analyst estimates of $24.94 million. During the same quarter last year, the firm posted ($1.03) earnings per share. The company’s quarterly revenue was down 8.3% compared to the same quarter last year.

Hedge Funds Weigh In On Arcus Biosciences

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. GAMMA Investing LLC raised its stake in shares of Arcus Biosciences by 59.1% in the third quarter. GAMMA Investing LLC now owns 2,748 shares of the company’s stock valued at $37,000 after acquiring an additional 1,021 shares during the last quarter. Hantz Financial Services Inc. increased its holdings in Arcus Biosciences by 121.9% during the 4th quarter. Hantz Financial Services Inc. now owns 1,604 shares of the company’s stock valued at $38,000 after purchasing an additional 881 shares in the last quarter. SBI Securities Co. Ltd. increased its holdings in Arcus Biosciences by 13,547.6% during the 3rd quarter. SBI Securities Co. Ltd. now owns 2,866 shares of the company’s stock valued at $39,000 after purchasing an additional 2,845 shares in the last quarter. T. Rowe Price Investment Management Inc. bought a new position in Arcus Biosciences in the 4th quarter valued at $39,000. Finally, CWM LLC boosted its stake in Arcus Biosciences by 233.6% in the second quarter. CWM LLC now owns 5,441 shares of the company’s stock worth $44,000 after purchasing an additional 3,810 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling at Arcus Biosciences

In related news, President Juan C. Jaen sold 82,997 shares of the stock in a transaction dated Thursday, December 4th. The shares were sold at an average price of $24.71, for a total value of $2,050,855.87. Following the completion of the transaction, the president owned 954,063 shares of the company’s stock, valued at $23,574,896.73. This represents a 8.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Jennifer Jarrett sold 11,225 shares of the firm’s stock in a transaction dated Tuesday, December 16th. The stock was sold at an average price of $21.88, for a total transaction of $245,603.00. Following the transaction, the chief operating officer owned 203,007 shares of the company’s stock, valued at approximately $4,441,793.16. This represents a 5.24% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders sold a total of 263,987 shares of company stock valued at $6,025,620 over the last quarter. 9.60% of the stock is currently owned by insiders.

Trending Headlines about Arcus Biosciences

Here are the key news stories impacting Arcus Biosciences this week:

• Positive Sentiment: Analysts’ aggregate view remains constructive — Arcus received an average recommendation of “Moderate Buy” from the analyst community, which supports investor demand. Arcus Receives Average Recommendation
• Positive Sentiment: HC Wainwright raised several near‑term and later‑year estimates (Q1 and Q2 2026 EPS were revised up; FY2028 and FY2029 loss forecasts improved) and reiterated a Buy rating with a $32 price target — that retained Buy conviction can buoy the stock despite mixed cuts elsewhere. MarketBeat RCUS
• Neutral Sentiment: Wall Street Zen upgraded Arcus to a Hold — an incremental change in street coverage that may temper volatility but is not an outright positive endorsement. Arcus Upgraded to Hold
• Neutral Sentiment: Analysts published longer‑range forecasts (FY2030 coverage), adding modelling detail for investors but without an immediate clear directional impact. Analysts Issue FY2030 Forecasts
• Negative Sentiment: Offsetting the positives, HC Wainwright increased loss projections for FY2026 (now -$4.66 vs. prior -$4.00) and raised Q3/Q4 2026 loss estimates — these larger near‑term losses are a negative earnings surprise risk and could weigh on sentiment if cash burn or trial timelines disappoint. HC Wainwright Estimate Changes

About Arcus Biosciences

Arcus Biosciences is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel cancer immunotherapies. The company’s research platform centers on modulating tumor microenvironments and immune checkpoints through both small-molecule and antibody-based candidates. Arcus aims to enhance antitumor immune responses by targeting pathways such as the adenosine axis and inhibitory receptors on immune cells.

The company’s lead clinical programs include etrumadenant, an orally administered A2A adenosine receptor antagonist being evaluated in combination with anti-PD-1 therapy, and domvanalimab, an anti-TIGIT monoclonal antibody.